FI105681B - Menetelmä terapeuttisesti käyttökelpoisen isopropyyli-(2-metoksietyyli)-4-(2-kloori-3-syaanifenyyli)-1,4-dihydro- 2,6-dimetyylipyridiini-3,5-dikarboksylaatin valmistamiseksi sekä menetelmän välituote - Google Patents

Menetelmä terapeuttisesti käyttökelpoisen isopropyyli-(2-metoksietyyli)-4-(2-kloori-3-syaanifenyyli)-1,4-dihydro- 2,6-dimetyylipyridiini-3,5-dikarboksylaatin valmistamiseksi sekä menetelmän välituote Download PDF

Info

Publication number: FI105681B
Authority: FI; Finland
Prior art keywords: formula; chloro; compound; preparation; cyanophenyl
Prior art date: 1993-12-10

Application number

FI945777A

Other languages

English (en)

Finnish (fi)

Swedish (sv)

Other versions

FI945777A7 (fi

FI945777A0 (fi

Inventor

Bodo Junge

Teunis Schuurman

Zhan Gao

Bernard Schmidt

Jonge Maarten De

Heinrich Meier

Wolfgang Hartwig

Rudolfy Schohe-Loop

Original Assignee

Bayer Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-12-10

Filing date

1994-12-08

Publication date

2000-09-29

1993-12-10 Priority claimed from DE4342194A external-priority patent/DE4342194A1/de

1994-07-13 Priority claimed from DE19944424677 external-priority patent/DE4424677A1/de

1994-12-08 Application filed by Bayer Ag filed Critical Bayer Ag

1994-12-08 Publication of FI945777A0 publication Critical patent/FI945777A0/fi

1995-06-11 Publication of FI945777A7 publication Critical patent/FI945777A7/fi

2000-09-29 Application granted granted Critical

2000-09-29 Publication of FI105681B publication Critical patent/FI105681B/fi

Links

238000000034 method Methods 0.000 title claims abstract description 27
238000002360 preparation method Methods 0.000 title claims abstract description 17
230000008569 process Effects 0.000 title claims abstract description 16
KJLJYTLPUUKRCU-UHFFFAOYSA-N CC(C)OC(=O)C1=C(C)N(CCOC)C(C)=C(C(O)=O)C1C1=CC=CC(C#N)=C1Cl Chemical compound CC(C)OC(=O)C1=C(C)N(CCOC)C(C)=C(C(O)=O)C1C1=CC=CC(C#N)=C1Cl KJLJYTLPUUKRCU-UHFFFAOYSA-N 0.000 title description 2
-1 compound rac-isopropyl 2-methoxyethyl 4-(2-chloro-3-cyanophenyl)-1,4-dihydro-2,6-dimethylpyridine-3,5-dicarb oxylate Chemical class 0.000 claims abstract description 15
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims abstract description 7
150000001875 compounds Chemical class 0.000 claims description 33
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 14
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
238000006243 chemical reaction Methods 0.000 claims description 13
MVYGQIWGZGMFAU-UHFFFAOYSA-N 2-chloro-3-formylbenzonitrile Chemical compound ClC1=C(C=O)C=CC=C1C#N MVYGQIWGZGMFAU-UHFFFAOYSA-N 0.000 claims description 8
150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 7
150000001298 alcohols Chemical class 0.000 claims description 5
239000012442 inert solvent Substances 0.000 claims description 5
238000004587 chromatography analysis Methods 0.000 claims description 4
150000007529 inorganic bases Chemical class 0.000 claims description 4
239000000546 pharmaceutical excipient Substances 0.000 claims description 3
JEMFYCFWXQJCPM-UHFFFAOYSA-N propan-2-yl 2-aminobut-2-enoate Chemical compound CC=C(N)C(=O)OC(C)C JEMFYCFWXQJCPM-UHFFFAOYSA-N 0.000 claims description 3
239000007790 solid phase Substances 0.000 claims description 3
125000001424 substituent group Chemical group 0.000 claims description 3
235000014653 Carica parviflora Nutrition 0.000 claims 1
241000243321 Cnidaria Species 0.000 claims 1
229940099352 cholate Drugs 0.000 claims 1
BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 claims 1
230000002490 cerebral effect Effects 0.000 abstract description 2
230000001537 neural effect Effects 0.000 abstract 1
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 12
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
239000000543 intermediate Substances 0.000 description 12
241000700159 Rattus Species 0.000 description 11
238000012360 testing method Methods 0.000 description 11
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 10
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 8
239000000243 solution Substances 0.000 description 8
239000002904 solvent Substances 0.000 description 8
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 7
239000000203 mixture Substances 0.000 description 7
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 6
230000000694 effects Effects 0.000 description 6
UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 5
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
229960000715 nimodipine Drugs 0.000 description 5
RBHUDDGPJRWBTF-UHFFFAOYSA-N 2-chloro-3-methylbenzonitrile Chemical compound CC1=CC=CC(C#N)=C1Cl RBHUDDGPJRWBTF-UHFFFAOYSA-N 0.000 description 4
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 4
229960000583 acetic acid Drugs 0.000 description 4
239000004480 active ingredient Substances 0.000 description 4
239000003814 drug Substances 0.000 description 4
238000001704 evaporation Methods 0.000 description 4
230000008020 evaporation Effects 0.000 description 4
239000000902 placebo Substances 0.000 description 4
229940068196 placebo Drugs 0.000 description 4
238000010992 reflux Methods 0.000 description 4
239000000741 silica gel Substances 0.000 description 4
229910002027 silica gel Inorganic materials 0.000 description 4
SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 4
239000000126 substance Substances 0.000 description 4
IPSCCQWFBATQLK-UHFFFAOYSA-N 4-(2-chloro-3-cyanophenyl)-5-(2-methoxyethoxycarbonyl)-2,6-dimethyl-1,4-dihydropyridine-3-carboxylic acid Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(O)=O)C1C1=CC=CC(C#N)=C1Cl IPSCCQWFBATQLK-UHFFFAOYSA-N 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
206010012289 Dementia Diseases 0.000 description 3
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
206010020772 Hypertension Diseases 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 3
238000010171 animal model Methods 0.000 description 3
239000002585 base Substances 0.000 description 3
210000004556 brain Anatomy 0.000 description 3
PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 3
239000003054 catalyst Substances 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
238000001816 cooling Methods 0.000 description 3
239000012043 crude product Substances 0.000 description 3
229940079593 drug Drugs 0.000 description 3
239000000706 filtrate Substances 0.000 description 3
125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 3
PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 3
239000000047 product Substances 0.000 description 3
238000003756 stirring Methods 0.000 description 3
YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical class C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 description 2
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
PAMIQIKDUOTOBW-UHFFFAOYSA-N 1-methylpiperidine Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 description 2
PAQZWJGSJMLPMG-UHFFFAOYSA-N 2,4,6-tripropyl-1,3,5,2$l^{5},4$l^{5},6$l^{5}-trioxatriphosphinane 2,4,6-trioxide Chemical compound CCCP1(=O)OP(=O)(CCC)OP(=O)(CCC)O1 PAQZWJGSJMLPMG-UHFFFAOYSA-N 0.000 description 2
KZIUQKCRAYTVFZ-UHFFFAOYSA-N 2-chloro-3-(dibromomethyl)benzonitrile Chemical compound ClC1=C(C#N)C=CC=C1C(Br)Br KZIUQKCRAYTVFZ-UHFFFAOYSA-N 0.000 description 2
125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 2
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
239000002253 acid Substances 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
150000001299 aldehydes Chemical class 0.000 description 2
230000001430 anti-depressive effect Effects 0.000 description 2
230000037396 body weight Effects 0.000 description 2
230000031709 bromination Effects 0.000 description 2
238000005893 bromination reaction Methods 0.000 description 2
150000001718 carbodiimides Chemical class 0.000 description 2
125000004925 dihydropyridyl group Chemical group N1(CC=CC=C1)* 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
229910052736 halogen Inorganic materials 0.000 description 2
229930195733 hydrocarbon Natural products 0.000 description 2
230000001631 hypertensive effect Effects 0.000 description 2
238000002844 melting Methods 0.000 description 2
230000008018 melting Effects 0.000 description 2
239000000825 pharmaceutical preparation Substances 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
230000009467 reduction Effects 0.000 description 2
238000000926 separation method Methods 0.000 description 2
150000003378 silver Chemical class 0.000 description 2
229910001961 silver nitrate Inorganic materials 0.000 description 2
239000012312 sodium hydride Substances 0.000 description 2
229910000104 sodium hydride Inorganic materials 0.000 description 2
239000007858 starting material Substances 0.000 description 2
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
125000005270 trialkylamine group Chemical group 0.000 description 2
XLOLWBTYFFTMCW-UHFFFAOYSA-N 1,2,3,5,6,7-hexahydroimidazo[1,5-a]pyridine Chemical compound C1CCN2CNCC2=C1 XLOLWBTYFFTMCW-UHFFFAOYSA-N 0.000 description 1
IRFSXVIRXMYULF-UHFFFAOYSA-N 1,2-dihydroquinoline Chemical compound C1=CC=C2C=CCNC2=C1 IRFSXVIRXMYULF-UHFFFAOYSA-N 0.000 description 1
ZXSQEZNORDWBGZ-UHFFFAOYSA-N 1,3-dihydropyrrolo[2,3-b]pyridin-2-one Chemical compound C1=CN=C2NC(=O)CC2=C1 ZXSQEZNORDWBGZ-UHFFFAOYSA-N 0.000 description 1
238000005160 1H NMR spectroscopy Methods 0.000 description 1
FEPAYYYXSMWSLX-UHFFFAOYSA-N 2-ethyl-5-phenyl-3h-1,2-oxazole-3-sulfonic acid Chemical compound OS(=O)(=O)C1N(CC)OC(C=2C=CC=CC=2)=C1 FEPAYYYXSMWSLX-UHFFFAOYSA-N 0.000 description 1
XLLIQLLCWZCATF-UHFFFAOYSA-N 2-methoxyethyl acetate Chemical compound COCCOC(C)=O XLLIQLLCWZCATF-UHFFFAOYSA-N 0.000 description 1
YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 1
HVCNXQOWACZAFN-UHFFFAOYSA-N 4-ethylmorpholine Chemical compound CCN1CCOCC1 HVCNXQOWACZAFN-UHFFFAOYSA-N 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
201000006474 Brain Ischemia Diseases 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
206010008120 Cerebral ischaemia Diseases 0.000 description 1
AKYHYWINOSSCIF-UHFFFAOYSA-N Cl(=O)(=O)(=O)O.C(C)(C)(C)N1OC(=CC1)C Chemical compound Cl(=O)(=O)(=O)O.C(C)(C)(C)N1OC(=CC1)C AKYHYWINOSSCIF-UHFFFAOYSA-N 0.000 description 1
206010012335 Dependence Diseases 0.000 description 1
208000020401 Depressive disease Diseases 0.000 description 1
XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
206010015150 Erythema Diseases 0.000 description 1
206010026749 Mania Diseases 0.000 description 1
206010061285 Mental disorder due to a general medical condition Diseases 0.000 description 1
208000019695 Migraine disease Diseases 0.000 description 1
208000005314 Multi-Infarct Dementia Diseases 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
208000005374 Poisoning Diseases 0.000 description 1
241000700157 Rattus norvegicus Species 0.000 description 1
BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
208000006011 Stroke Diseases 0.000 description 1
208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 1
208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
229920002807 Thiomer Polymers 0.000 description 1
201000004810 Vascular dementia Diseases 0.000 description 1
230000009471 action Effects 0.000 description 1
230000001476 alcoholic effect Effects 0.000 description 1
239000003513 alkali Substances 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
150000001340 alkali metals Chemical class 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
150000003927 aminopyridines Chemical class 0.000 description 1
208000007502 anemia Diseases 0.000 description 1
230000003276 anti-hypertensive effect Effects 0.000 description 1
239000000935 antidepressant agent Substances 0.000 description 1
229940005513 antidepressants Drugs 0.000 description 1
229910052786 argon Inorganic materials 0.000 description 1
230000001174 ascending effect Effects 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
230000003542 behavioural effect Effects 0.000 description 1
125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
238000009835 boiling Methods 0.000 description 1
230000005978 brain dysfunction Effects 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
150000004649 carbonic acid derivatives Chemical class 0.000 description 1
150000001728 carbonyl compounds Chemical class 0.000 description 1
150000007942 carboxylates Chemical class 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
206010008118 cerebral infarction Diseases 0.000 description 1
208000026106 cerebrovascular disease Diseases 0.000 description 1
230000008859 change Effects 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
239000013078 crystal Substances 0.000 description 1
125000004093 cyano group Chemical group *C#N 0.000 description 1
125000004802 cyanophenyl group Chemical group 0.000 description 1
230000007423 decrease Effects 0.000 description 1
230000003412 degenerative effect Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
125000005265 dialkylamine group Chemical group 0.000 description 1
SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 1
229940085304 dihydropyridine derivative selective calcium channel blockers with mainly vascular effects Drugs 0.000 description 1
IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
239000003480 eluent Substances 0.000 description 1
238000010828 elution Methods 0.000 description 1
231100000321 erythema Toxicity 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
125000004494 ethyl ester group Chemical group 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
238000001914 filtration Methods 0.000 description 1
238000003818 flash chromatography Methods 0.000 description 1
239000011888 foil Substances 0.000 description 1
239000012362 glacial acetic acid Substances 0.000 description 1
239000011521 glass Substances 0.000 description 1
244000144993 groups of animals Species 0.000 description 1
150000008282 halocarbons Chemical class 0.000 description 1
150000002367 halogens Chemical group 0.000 description 1
GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
150000004678 hydrides Chemical class 0.000 description 1
150000002430 hydrocarbons Chemical class 0.000 description 1
ORTFAQDWJHRMNX-UHFFFAOYSA-N hydroxidooxidocarbon(.) Chemical compound O[C]=O ORTFAQDWJHRMNX-UHFFFAOYSA-N 0.000 description 1
150000003949 imides Chemical class 0.000 description 1
229910052738 indium Inorganic materials 0.000 description 1
208000014674 injury Diseases 0.000 description 1
230000001678 irradiating effect Effects 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical class C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
230000000366 juvenile effect Effects 0.000 description 1
230000007786 learning performance Effects 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
230000006386 memory function Effects 0.000 description 1
206010027175 memory impairment Diseases 0.000 description 1
230000007334 memory performance Effects 0.000 description 1
208000030159 metabolic disease Diseases 0.000 description 1
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
244000005700 microbiome Species 0.000 description 1
206010027599 migraine Diseases 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
KCXYZMFPZHYUFO-UHFFFAOYSA-N n-methyl-n-phosphanylmethanamine Chemical compound CN(C)P KCXYZMFPZHYUFO-UHFFFAOYSA-N 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
208000015122 neurodegenerative disease Diseases 0.000 description 1
201000001119 neuropathy Diseases 0.000 description 1
230000007823 neuropathy Effects 0.000 description 1
239000012454 non-polar solvent Substances 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
231100000572 poisoning Toxicity 0.000 description 1
230000000607 poisoning effect Effects 0.000 description 1
235000011181 potassium carbonates Nutrition 0.000 description 1
239000012286 potassium permanganate Substances 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
239000000376 reactant Substances 0.000 description 1
230000004044 response Effects 0.000 description 1
238000007363 ring formation reaction Methods 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
238000004904 shortening Methods 0.000 description 1
229910052709 silver Inorganic materials 0.000 description 1
239000004332 silver Substances 0.000 description 1
LKZMBDSASOBTPN-UHFFFAOYSA-L silver carbonate Substances [Ag].[O-]C([O-])=O LKZMBDSASOBTPN-UHFFFAOYSA-L 0.000 description 1
229910001958 silver carbonate Inorganic materials 0.000 description 1
229910001494 silver tetrafluoroborate Inorganic materials 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
235000011182 sodium carbonates Nutrition 0.000 description 1
239000007787 solid Substances 0.000 description 1
241000894007 species Species 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
238000005507 spraying Methods 0.000 description 1
230000009182 swimming Effects 0.000 description 1
238000004809 thin layer chromatography Methods 0.000 description 1
230000008733 trauma Effects 0.000 description 1
MVDRXYIEGOGRAI-UHFFFAOYSA-N tribromomethylbenzene Chemical compound BrC(Br)(Br)C1=CC=CC=C1 MVDRXYIEGOGRAI-UHFFFAOYSA-N 0.000 description 1
238000012800 visualization Methods 0.000 description 1
239000012224 working solution Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
- C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Neurology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Psychiatry (AREA)
Cardiology (AREA)
Hospice & Palliative Care (AREA)
Heart & Thoracic Surgery (AREA)
Pain & Pain Management (AREA)
Epidemiology (AREA)
Hydrogenated Pyridines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Liquid Crystal Substances (AREA)

FI945777A 1993-12-10 1994-12-08 Menetelmä terapeuttisesti käyttökelpoisen isopropyyli-(2-metoksietyyli)-4-(2-kloori-3-syaanifenyyli)-1,4-dihydro- 2,6-dimetyylipyridiini-3,5-dikarboksylaatin valmistamiseksi sekä menetelmän välituote FI105681B (fi)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
DE4342194		1993-12-10
DE4342194A DE4342194A1 (de)	1993-12-10	1993-12-10	Halogen-phenyl-substituierte 1,4-Dihydropyridine
DE19944424677 DE4424677A1 (de)	1994-07-13	1994-07-13	Isopropyl-(2-methoxyethyl)-4-(2-chlor-3-cyano-phenyl)-1,4-dihydro-2,6-dimethyl-pyridin-3,5-dicarboxylat
DE4424677		1994-07-13

Publications (3)

Publication Number	Publication Date
FI945777A0 FI945777A0 (fi)	1994-12-08
FI945777A7 FI945777A7 (fi)	1995-06-11
FI105681B true FI105681B (fi)	2000-09-29

Family

ID=25931956

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FI945777A FI105681B (fi)	1993-12-10	1994-12-08	Menetelmä terapeuttisesti käyttökelpoisen isopropyyli-(2-metoksietyyli)-4-(2-kloori-3-syaanifenyyli)-1,4-dihydro- 2,6-dimetyylipyridiini-3,5-dikarboksylaatin valmistamiseksi sekä menetelmän välituote

Country Status (35)

Country	Link
US (1)	US5665740A (da)
EP (1)	EP0657430B1 (da)
JP (1)	JP3751041B2 (da)
KR (1)	KR100332325B1 (da)
CN (2)	CN1056606C (da)
AT (1)	ATE180774T1 (da)
AU (1)	AU686976B2 (da)
BG (1)	BG62487B1 (da)
CA (1)	CA2137525C (da)
CO (1)	CO4290426A1 (da)
CU (1)	CU22713A3 (da)
CZ (1)	CZ286065B6 (da)
DE (1)	DE59408350D1 (da)
DK (1)	DK0657430T3 (da)
DZ (1)	DZ1831A1 (da)
EE (1)	EE03192B1 (da)
ES (1)	ES2132308T3 (da)
FI (1)	FI105681B (da)
GR (1)	GR3030436T3 (da)
HR (1)	HRP940967B1 (da)
HU (1)	HU215593B (da)
IL (1)	IL111922A (da)
LV (1)	LV11321B (da)
MA (1)	MA23392A1 (da)
MY (1)	MY111976A (da)
NO (1)	NO302362B1 (da)
NZ (1)	NZ270087A (da)
PL (1)	PL179973B1 (da)
RO (1)	RO115800B1 (da)
SA (1)	SA95160078B1 (da)
SK (1)	SK282399B6 (da)
SV (1)	SV1994000072A (da)
TN (1)	TNSN94127A1 (da)
TW (1)	TW412529B (da)
YU (1)	YU48920B (da)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2546395A1 (en) *	2003-11-21	2005-06-09	Memory Pharmaceutical Corporation	Compositions and methods of treatment using l-type calcium channel blockers and cholinesterase inhibitors
WO2008058234A2 (en) *	2006-11-08	2008-05-15	Memory Pharmaceuticals Corporation	Pharmaceutical formulations for 1,4-dihyrdropyridine compounds having improved solubility
US11512052B2 (en) *	2017-11-21	2022-11-29	Icahn School Of Medicine At Mount Sinai	Dihydropyridines for the treatment of cognitive impairment or traumatic brain injury

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE1963188A1 (de) *	1969-12-17	1971-06-24	Bayer Ag	Neue Cyanphenyl-1,4-dihydropyridinderivate
US3932646A (en) *	1971-04-10	1976-01-13	Farbenfabriken Bayer Ag	Pharmaceutical compositions containing unsymmetrical esters of 1,4-dihydropyridine 3,5-dicarboxylate
DE2117572C3 (de) *	1971-04-10	1980-03-20	Bayer Ag, 5090 Leverkusen	Unsymmetrische 1,4-Dihydropyridin ^-dicarbonsäureester, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Arzneimittel
DE2508181A1 (de) *	1975-02-26	1976-09-09	Bayer Ag	1,4-dihydropyridincarbonsaeurearal- kylester, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
DE2815578C2 (de) *	1978-04-11	1986-01-16	Bayer Ag, 5090 Leverkusen	Neue pharmazeutische Verwendung von Nimodipin
DE2935451A1 (de) *	1979-09-01	1981-03-19	Bayer Ag, 5090 Leverkusen	Optisch aktive 1,4-dihydropyridine, verfahren zu ihrer herstellung und ihre verwendung als arneimittel
DE3208628A1 (de) *	1982-03-10	1983-09-22	Bayer Ag, 5090 Leverkusen	Neue verbindungen, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
DE3239273A1 (de) *	1982-10-23	1984-04-26	Bayer Ag, 5090 Leverkusen	Tetrahydropyridine, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
US5137889A (en) *	1983-12-02	1992-08-11	Otsuka Pharmaceutical Co., Ltd.	Dihydropyridine derivatives and process for preparing the same
DE3718398A1 (de) *	1987-06-02	1988-12-22	Troponwerke Gmbh & Co Kg	Neue kombinationspraeparate mit antidepressiver wirkung
US5114946A (en) *	1987-06-12	1992-05-19	American Cyanamid Company	Transdermal delivery of pharmaceuticals
DE3806277A1 (de) *	1988-02-27	1989-09-07	Troponwerke Gmbh & Co Kg	Verwendung von 1,4-dihydropyridin-derivaten
DE4011695A1 (de) *	1990-04-11	1991-10-17	Bayer Ag	Verwendung von n-alkylierten 1,4-dihydropyridindicarbonsaeureestern als arzneimittel, neue verbindungen und verfahren zu ihrer herstellung
FR2671349B1 (fr) *	1991-01-09	1993-04-23	Lafon Labor	Nouveaux derives de 1,4-dihydropyridine, leur procede de preparation et composition therapeutique les contenant.
DE4125271A1 (de) *	1991-07-31	1993-02-11	Bayer Ag	Neue n-alkylierte 1,4-dihydropyridindicarbonsaeureester

1994
- 1994-11-22 EE EE9400393A patent/EE03192B1/xx not_active IP Right Cessation
- 1994-11-28 AT AT94118671T patent/ATE180774T1/de active
- 1994-11-28 EP EP94118671A patent/EP0657430B1/de not_active Expired - Lifetime
- 1994-11-28 DE DE59408350T patent/DE59408350D1/de not_active Expired - Lifetime
- 1994-11-28 ES ES94118671T patent/ES2132308T3/es not_active Expired - Lifetime
- 1994-11-28 DK DK94118671T patent/DK0657430T3/da active
- 1994-12-01 HR HRP4424677.3A patent/HRP940967B1/xx not_active IP Right Cessation
- 1994-12-02 CU CU13794A patent/CU22713A3/es unknown
- 1994-12-02 US US08/348,436 patent/US5665740A/en not_active Expired - Lifetime
- 1994-12-02 CO CO94055078A patent/CO4290426A1/es unknown
- 1994-12-06 JP JP32981994A patent/JP3751041B2/ja not_active Expired - Fee Related
- 1994-12-06 RO RO94-01950A patent/RO115800B1/ro unknown
- 1994-12-07 PL PL94306157A patent/PL179973B1/pl not_active IP Right Cessation
- 1994-12-07 SK SK1516-94A patent/SK282399B6/sk not_active IP Right Cessation
- 1994-12-07 TN TNTNSN94127A patent/TNSN94127A1/fr unknown
- 1994-12-07 CA CA002137525A patent/CA2137525C/en not_active Expired - Fee Related
- 1994-12-07 DZ DZ940128A patent/DZ1831A1/fr active
- 1994-12-07 IL IL11192294A patent/IL111922A/xx not_active IP Right Cessation
- 1994-12-07 NZ NZ270087A patent/NZ270087A/en not_active IP Right Cessation
- 1994-12-08 SV SV1994000072A patent/SV1994000072A/es not_active Application Discontinuation
- 1994-12-08 CZ CZ19943093A patent/CZ286065B6/cs not_active IP Right Cessation
- 1994-12-08 BG BG99249A patent/BG62487B1/bg unknown
- 1994-12-08 YU YU71794A patent/YU48920B/sh unknown
- 1994-12-08 AU AU80306/94A patent/AU686976B2/en not_active Ceased
- 1994-12-08 FI FI945777A patent/FI105681B/fi not_active IP Right Cessation
- 1994-12-09 NO NO944787A patent/NO302362B1/no not_active IP Right Cessation
- 1994-12-09 LV LVP-94-242A patent/LV11321B/lv unknown
- 1994-12-09 CN CN94112892A patent/CN1056606C/zh not_active Expired - Fee Related
- 1994-12-09 HU HU9403551A patent/HU215593B/hu not_active IP Right Cessation
- 1994-12-09 MA MA23720A patent/MA23392A1/fr unknown
- 1994-12-09 KR KR1019940033434A patent/KR100332325B1/ko not_active Expired - Fee Related
- 1994-12-09 MY MYPI94003289A patent/MY111976A/en unknown
1995
- 1995-02-14 TW TW084101294A patent/TW412529B/zh not_active IP Right Cessation
- 1995-06-28 SA SA95160078A patent/SA95160078B1/ar unknown
1999
- 1999-06-09 GR GR990401523T patent/GR3030436T3/el unknown
- 1999-06-30 CN CN99108967A patent/CN1124258C/zh not_active Expired - Fee Related

Also Published As

Publication number	Publication date
IL111922A (en)	1999-05-09
HU215593B (hu)	1999-01-28
HU9403551D0 (en)	1995-02-28
TNSN94127A1 (en)	1995-09-21
PL179973B1 (pl)	2000-11-30
TW412529B (en)	2000-11-21
FI945777A7 (fi)	1995-06-11
DE59408350D1 (de)	1999-07-08
YU48920B (sh)	2002-11-15
ATE180774T1 (de)	1999-06-15
CN1109874A (zh)	1995-10-11
KR100332325B1 (ko)	2002-09-04
CO4290426A1 (es)	1996-04-17
LV11321A (lv)	1996-06-20
NO302362B1 (no)	1998-02-23
DZ1831A1 (fr)	2002-02-17
CZ286065B6 (cs)	2000-01-12
CN1124258C (zh)	2003-10-15
SV1994000072A (es)	1995-08-09
BG99249A (en)	1995-09-29
JP3751041B2 (ja)	2006-03-01
EE03192B1 (et)	1999-06-15
BG62487B1 (bg)	1999-12-30
CZ309394A3 (en)	1995-11-15
LV11321B (en)	1996-12-20
JPH07242632A (ja)	1995-09-19
HUT70937A (en)	1995-11-28
HRP940967B1 (en)	1999-12-31
NO944787L (no)	1995-06-12
GR3030436T3 (en)	1999-09-30
FI945777A0 (fi)	1994-12-08
MY111976A (en)	2001-03-31
CN1056606C (zh)	2000-09-20
RO115800B1 (ro)	2000-06-30
NZ270087A (en)	1996-08-27
US5665740A (en)	1997-09-09
SA95160078B1 (ar)	2006-09-25
AU8030694A (en)	1995-06-15
PL306157A1 (en)	1995-06-12
CN1244525A (zh)	2000-02-16
YU71794A (sh)	1996-10-18
AU686976B2 (en)	1998-02-12
NO944787D0 (no)	1994-12-09
EP0657430A1 (de)	1995-06-14
HRP940967A2 (en)	1997-08-31
SK151694A3 (en)	1995-07-11
CA2137525A1 (en)	1995-06-11
IL111922A0 (en)	1995-03-15
MA23392A1 (fr)	1995-07-01
KR950017958A (ko)	1995-07-22
DK0657430T3 (da)	1999-11-15
CA2137525C (en)	2005-07-12
ES2132308T3 (es)	1999-08-16
SK282399B6 (sk)	2002-01-07
EP0657430B1 (de)	1999-06-02
CU22713A3 (es)	1996-07-05

Legal Events

Date

Code

Title

Description

2009-05-22

PC

Transfer of assignment of patent

Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT

Free format text: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT

2009-06-25

PC